Cross-validation of a new prognostic index integrating tumor marker decline in patients with relapsed disseminated germ cell tumors.

Abstract

5086 Background: Early serum tumor marker decline during chemotherapy was previously shown to be prognostic for progression-free survival (PFS) and overall survival (OS) in patients with relapsed GCT in an analysis of the IT94 phase III trial, which compared conventional chemotherapy versus high dose chemotherapy (Massard C, ASCO 2008. Abstract No. 5085… (More)

Topics

  • Presentations referencing similar topics